In Reversal, European Regulators Take Positive View on Lilly Alzheimer’s Drug

European regulators endorse Lilly's Alzheimer's treatment for certain patients

Regulators had initially said the drug should be rejected, but issued a limited approval recommendation following an appeal.

Lilly Gets Limited European Backing for Alzheimer’s Disease Drug

Eli Lilly & Co. won the backing of European Union regulators for its Alzheimer’s disease drug Kisunla in a specific group of patients, potentially paving the way for it to become the second drug in the region to slow the most common cause of dementia in the elderly.

In reversal, European regulators take positive view on Lilly Alzheimer’s drug

Lilly’s appeal of an earlier, negative recommendation from a key EMA committee has worked out in its favor, and puts the drug, Kisunla, one step closer to European market entry.